[1] Xu Q, Tao LY, Wu Q, et al. Prevalences of and risk factors for biliary stones and gallbladder polyps in a large Chinese population. HPB (Oxford),2012,14: 373-381.
[2] Zhu L, Aili A, Zhang C, et al. Prevalence of and risk factors for gallstones in Uighur and Han Chinese. World J Gastroenterol,2014,20: 14942-14949.
[3] Shen, SS,Gong, JJ,Wang, XW,et al. Promotional effect of nonalcoholic fatty liver disease on Gallstone disease: A systematic review and meta-analysis. Turk J Gastroenterol,2017, 28, 31-39.
[4] Biddinger SB,Haas JT,Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med, 2008, 14, 778-782.
[5] Ahmed MH,Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: Which comes first? Scand J Gastroenterol, 2014, 49, 521-527.
[6] Liu J, Lin H, Zhang C, et al. Nonalcoholic fatty liver disease associated with gallstones in females rather than males:a longitudinal cohort study in Chinese urban population. BMC Gastroenterol, 2014, 14:213.
[7] Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med, 2016, 26:364-373.
[8] Lin IC, Yang YW, Wu MF, et al. The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract, 2014, 15:138.
[9] Fracanzani AL, Valenti L, Russello M, et al. Gallstone disease is associated with more severe liver damage in patients with nonalcoholic fatty liver disease. PloS One, 2012, 7:e41183.
[10] Kitade H, Chen G,Ni Y,et al.Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients, 2017, 9.pii:E387.
[11] Cortes V, Quezada N, Uribe S, et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in nonobese Hispanic patients: a pilot study. Lipids in health and disease, 2017, 16:129.
[12] Noel OF, Still CD, Argyropoulos G, et al. Bile acids, FXR, and Metabolic Effects of Bariatric Surgery. J Obes, 2016, 2016: 4390254.
[13] Rosso C, Mezzabotta L, Gaggini M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology, 2016, 63:107-116.
[14] Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology, 2014, 146:726-735.
[15] Uppal H, Zhai Y, Gangopadhyay A, et al. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology, 2008, 47:1331-1342.
[16] Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology, 2017, 65:350-362.
[17] Yu DD, Andrali SS, Li H, et al. Novel FXR (farnesoid X receptor) modulators: potential therapies for cholesterol gallstone disease. Bioorg Med Chem, 2016, 24:3986-3993.
[18] Deutschmann K, Reich M, Klindt C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta, 2017.
[19] Barrera F, Azocar L, Molina H, et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of broblast growth factor 19. Ann Hepatol, 2015, 14:710-721.
[20] Keitel V, Haussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol, 2012, 36:412-419. |
